RxSight Inc (RXST) concluded trading on Thursday at a closing price of $16.21, with 5.73 million shares of worth about $92.87 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -65.62% during that period and on April 03, 2025 the price saw a loss of about -37.94%. Currently the company’s common shares owned by public are about 40.43M shares, out of which, 38.38M shares are available for trading.
Stock saw a price change of -39.22% in past 5 days and over the past one month there was a price change of -39.04%. Year-to-date (YTD), RXST shares are showing a performance of -52.85% which decreased to -67.85% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.09 but also hit the highest price of $66.54 during that period. The average intraday trading volume for RxSight Inc shares is 612.62K. The stock is currently trading -35.07% below its 20-day simple moving average (SMA20), while that difference is down -43.11% for SMA50 and it goes to -61.99% lower than SMA200.
RxSight Inc (NASDAQ: RXST) currently have 40.43M outstanding shares and institutions hold larger chunk of about 87.20% of that.
The stock has a current market capitalization of $656.35M and its 3Y-monthly beta is at 1.25. It has posted earnings per share of -$0.71 in the same period. It has Quick Ratio of 10.50 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RXST, volatility over the week remained 6.41% while standing at 5.02% over the month.
Stock’s fiscal year EPS is expected to rise by 17.36% while it is estimated to increase by 35.77% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on April 03, 2025 offering an Underperform rating for the stock and assigned a target price range of between $36 and $22 to it. Coverage by Stifel stated RxSight Inc (RXST) stock as a Hold in their note to investors on December 20, 2024, suggesting a price target of $40 for the stock. On December 11, 2024, Wells Fargo Downgrade their recommendations, while on December 06, 2024, UBS Initiated their ratings for the stock with a price target of $52. Stock get a Buy rating from Jefferies on October 29, 2024.
